Literature DB >> 15240691

Specific engagement of TLR4 or TLR3 does not lead to IFN-beta-mediated innate signal amplification and STAT1 phosphorylation in resident murine alveolar macrophages.

Antonello Punturieri1, Rebecca S Alviani, Timothy Polak, Phil Copper, Joanne Sonstein, Jeffrey L Curtis.   

Abstract

The innate immune response must be mobilized promptly yet judiciously via TLRs to protect the lungs against pathogens. Stimulation of murine peritoneal macrophage (PMphi) TLR4 or TLR3 by pathogen-associated molecular patterns (PAMPs) typically induces type I IFN-beta, leading to autocrine activation of the transcription factor STAT1. Because it is unknown whether STAT1 plays a similar role in the lungs, we studied the response of resident alveolar macrophages (AMphi) or control PMphi from normal C57BL/6 mice to stimulation by PAMPs derived from viruses (polyriboinosinic:polyribocytidylic acid, specific for TLR3) or bacteria (Pam(3)Cys, specific for TLR2, and repurified LPS, specific for TLR4). AMphi did not activate STAT1 by tyrosine phosphorylation on Y701 following stimulation of any of these three TLRs, but readily did so in response to exogenous IFN-beta. This unique AMphi response was not due to altered TLR expression, or defective immediate-early gene response, as measured by expression of TNF-alpha and three beta chemokines. Instead, AMphi differed from PMphi in not producing bioactive IFN-beta, as confirmed by ELISA and by the failure of supernatants from TLR-stimulated AMphi to induce STAT1 phosphorylation in PMphi. Consequently, AMphi did not produce the microbicidal effector molecule NO following TLR4 or TLR3 stimulation unless exogenous IFN-beta was also added. Thus, murine AMphi respond to bacterial or viral PAMPs by producing inflammatory cytokines and chemokines, but because they lack the feed-forward amplification typically mediated by autocrine IFN-beta secretion and STAT1 activation, require exogenous IFN to mount a second phase of host defense.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240691      PMCID: PMC2701405          DOI: 10.4049/jimmunol.173.2.1033

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Enhancing antitumor immunity perioperatively: a matter of timing, cooperation, and specificity.

Authors:  Jeffrey L Curtis; Antonello Punturieri
Journal:  Am J Respir Cell Mol Biol       Date:  2003-05       Impact factor: 6.914

Review 2.  How we detect microbes and respond to them: the Toll-like receptors and their transducers.

Authors:  B Beutler; K Hoebe; X Du; R J Ulevitch
Journal:  J Leukoc Biol       Date:  2003-07-01       Impact factor: 4.962

3.  Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages.

Authors:  Sang Hoon Rhee; Bryan W Jones; Vladimir Toshchakov; Stefanie N Vogel; Matthew J Fenton
Journal:  J Biol Chem       Date:  2003-04-09       Impact factor: 5.157

4.  Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells.

Authors:  Sandra Hodge; Greg Hodge; Raffaele Scicchitano; Paul N Reynolds; Mark Holmes
Journal:  Immunol Cell Biol       Date:  2003-08       Impact factor: 5.126

5.  Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.

Authors:  Masahiro Yamamoto; Shintaro Sato; Hiroaki Hemmi; Katsuaki Hoshino; Tsuneyasu Kaisho; Hideki Sanjo; Osamu Takeuchi; Masanaka Sugiyama; Masaru Okabe; Kiyoshi Takeda; Shizuo Akira
Journal:  Science       Date:  2003-07-10       Impact factor: 47.728

Review 6.  Role of adapters in Toll-like receptor signalling.

Authors:  S Akira; M Yamamoto; K Takeda
Journal:  Biochem Soc Trans       Date:  2003-06       Impact factor: 5.407

7.  Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection.

Authors:  Kenya Honda; Shinya Sakaguchi; Chigusa Nakajima; Ai Watanabe; Hideyuki Yanai; Misako Matsumoto; Toshiaki Ohteki; Tsuneyasu Kaisho; Akinori Takaoka; Shizuo Akira; Tsukasa Seya; Tadatsugu Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

8.  Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis.

Authors:  Shuo Zheng; Bishnu P De; Suresh Choudhary; Suzy A A Comhair; Tannishia Goggans; Roger Slee; Bryan R G Williams; Joseph Pilewski; S Jaharul Haque; Serpil C Erzurum
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

Review 9.  The Toll-IL-1 receptor adaptor family grows to five members.

Authors:  Luke A J O'Neill; Katherine A Fitzgerald; Andrew G Bowie
Journal:  Trends Immunol       Date:  2003-06       Impact factor: 16.687

10.  Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients.

Authors:  Rany Condos; Bindu Raju; Antony Canova; Ben-Yang Zhao; Michael Weiden; William N Rom; Richard Pine
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

View more
  15 in total

Review 1.  Cell-mediated adaptive immune defense of the lungs.

Authors:  Jeffrey L Curtis
Journal:  Proc Am Thorac Soc       Date:  2005

Review 2.  Should we inhibit type I interferons in sepsis?

Authors:  Tina Mahieu; Claude Libert
Journal:  Infect Immun       Date:  2006-09-25       Impact factor: 3.441

3.  Conserved nontypeable Haemophilus influenzae-derived TLR2-binding lipopeptides synergize with IFN-beta to increase cytokine production by resident murine and human alveolar macrophages.

Authors:  Antonello Punturieri; Phil Copper; Timothy Polak; Paul J Christensen; Jeffrey L Curtis
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

Review 4.  The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research.

Authors:  Jeffrey L Curtis; Christine M Freeman; James C Hogg
Journal:  Proc Am Thorac Soc       Date:  2007-10-01

5.  Staphylococcus aureus activates type I IFN signaling in mice and humans through the Xr repeated sequences of protein A.

Authors:  Francis J Martin; Marisa I Gomez; Dawn M Wetzel; Guido Memmi; Maghnus O'Seaghdha; Grace Soong; Christian Schindler; Alice Prince
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

6.  Virulence factors identified by Cryptococcus neoformans mutant screen differentially modulate lung immune responses and brain dissemination.

Authors:  Xiumiao He; Daniel M Lyons; Dena L Toffaletti; Fuyuan Wang; Yafeng Qiu; Michael J Davis; Daniel L Meister; Jeremy K Dayrit; Anthony Lee; John J Osterholzer; John R Perfect; Michal A Olszewski
Journal:  Am J Pathol       Date:  2012-07-28       Impact factor: 4.307

7.  Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis.

Authors:  Thomas H Sisson; Michael Mendez; Karen Choi; Natalya Subbotina; Anthony Courey; Andrew Cunningham; Aditi Dave; John F Engelhardt; Xiaoming Liu; Eric S White; Victor J Thannickal; Bethany B Moore; Paul J Christensen; Richard H Simon
Journal:  Am J Respir Crit Care Med       Date:  2009-10-22       Impact factor: 21.405

8.  Differential ex vivo nitric oxide production by acutely isolated neonatal and adult microglia.

Authors:  John B Schell; Courtney A Crane; Michael F Smith; Margo R Roberts
Journal:  J Neuroimmunol       Date:  2007-08-15       Impact factor: 3.478

9.  Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells.

Authors:  Julien Pothlichet; Isabelle Meunier; Beckley K Davis; Jenny P-Y Ting; Emil Skamene; Veronika von Messling; Silvia M Vidal
Journal:  PLoS Pathog       Date:  2013-04-11       Impact factor: 6.823

10.  Host Defense and the Airway Epithelium: Frontline Responses That Protect against Bacterial Invasion and Pneumonia.

Authors:  Nicholas A Eisele; Deborah M Anderson
Journal:  J Pathog       Date:  2011-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.